Autoimmune Disease Diagnostics Market Report
Published Date: 22 April 2026 | Report Code: autoimmune-disease-diagnostics
Autoimmune Disease Diagnostics Market Size, Share, Industry Trends and Forecast to 2033
This report provides an in-depth analysis of the Autoimmune Disease Diagnostics market, emphasizing market trends, growth forecasts, and competitive dynamics from 2023 to 2033.
Key Takeaways
- Global market expands from $8.70 Billion in 2023 to $17.78 Billion by 2033, reflecting a 7.2% CAGR over the forecast period.
- North America is both the largest and the fastest-growing region, advancing from $3.38 Billion to $6.91 Billion between 2023 and 2033.
- Europe and Asia Pacific show notable growth: Europe rises from $2.56 Billion to $5.24 Billion; Asia Pacific moves from $1.6 Billion to $3.27 Billion.
- Market activity is driven by technological upgrades in laboratories, increasing point-of-care adoption, and investments by major firms such as Abbott Laboratories and Thermo Fisher Scientific.
- Segment diversity covers test types, technologies, and end users including Hospitals, Clinical Laboratories, Home Care Settings, and Research Institutions.
Autoimmune Disease Diagnostics Market Report — Executive Summary
The Autoimmune Disease Diagnostics market is on an upward trajectory, growing from $8.70 Billion in 2023 toward $17.78 Billion by 2033 at a 7.2% CAGR over the 2023 to 2033 forecast interval. Expansion is propelled by improvements in laboratory instrumentation, wider use of point-of-care testing, and increasing clinical awareness of autoimmune conditions. The sector remains fragmented, with established firms—Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, and Becton, Dickinson and Company (BD)—competing alongside specialized innovators. Market segmentation spans test types (Laboratory Tests, Molecular Diagnostics, Imaging Techniques), technologies (Traditional, Advanced, Point of Care), automation levels (Manual to Fully Automated), and end users (Hospitals, Clinical Laboratories, Home Care Settings, Research Institutions). Regional patterns vary: North America leads in both scale and pace, while Europe and Asia Pacific demonstrate steady adoption supported by regulatory and infrastructure developments. Ongoing research, automation, and decentralized testing approaches are expected to shape future product development and service delivery models.
Key Growth Drivers
- Advances in laboratory instrumentation and diagnostic platforms enable more accurate and earlier detection of autoimmune disorders.
- Rising public and clinical awareness of autoimmune conditions increases demand for diagnostic testing and screening services.
- Growth in point-of-care and automated testing reduces turnaround times and expands access outside centralized laboratories.
- Increased healthcare spending and ongoing research activities support adoption of novel diagnostic techniques and expanded testing portfolios.
- Presence and product investment by leading companies strengthen distribution channels and accelerate technology diffusion.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $8.70 Billion |
| CAGR (2023-2033) | 7.2% |
| 2033 Market Size | $17.78 Billion |
| Top Companies | Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, Becton, Dickinson and Company (BD) |
| Last Modified Date | 22 April 2026 |
Autoimmune Disease Diagnostics Market Overview
Customize Autoimmune Disease Diagnostics Market Report market research report
- ✔ Get in-depth analysis of Autoimmune Disease Diagnostics market size, growth, and forecasts.
- ✔ Understand Autoimmune Disease Diagnostics's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Autoimmune Disease Diagnostics
What is the Market Size & CAGR of Autoimmune Disease Diagnostics Market Report market in 2023?
Autoimmune Disease Diagnostics Industry Analysis
Autoimmune Disease Diagnostics Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Autoimmune Disease Diagnostics Market Report Market Analysis Report by Region
Europe Autoimmune Disease Diagnostics Market Report:
From $2.56 Billion in 2023 growing to $5.24 Billion in 2033, Europe exhibits steady expansion supported by regulatory focus on diagnostic quality, growing clinical awareness of autoimmune diseases, and modernization of laboratory infrastructure across major markets.Asia Pacific Autoimmune Disease Diagnostics Market Report:
From $1.6 Billion in 2023 growing to $3.27 Billion in 2033, Asia Pacific shows meaningful growth as healthcare spending increases, access to diagnostics improves, and adoption of molecular and imaging techniques rises in clinical practice.North America Autoimmune Disease Diagnostics Market Report:
From $3.38 Billion in 2023 growing to $6.91 Billion in 2033, North America is both the largest and the fastest-growing region. Expansion is driven by advanced laboratory networks, strong healthcare investment, rapid uptake of automated and point-of-care diagnostics, and active participation from major suppliers.South America Autoimmune Disease Diagnostics Market Report:
Middle East & Africa Autoimmune Disease Diagnostics Market Report:
From $0.98 Billion in 2023 growing to $2 Billion in 2033, the Middle East and Africa region advances as healthcare infrastructure investments, increased disease awareness, and targeted research initiatives support wider diagnostic deployment.Tell us your focus area and get a customized research report.
Research Methodology
Autoimmune Disease Diagnostics Market Analysis By Test Type
The Autoimmune Disease Diagnostics market by test type is dominated by laboratory tests, with a market size of USD 5.49 billion in 2023, projected to increase to USD 11.22 billion by 2033, accounting for 63.07% share. Other significant segments include molecular diagnostics valued at USD 2.46 billion and imaging techniques at USD 0.76 billion in 2023, growing accordingly to USD 5.02 billion and USD 1.55 billion by 2033.
Autoimmune Disease Diagnostics Market Analysis By Automation Level
Market segmentation by level of automation shows significant demand for fully automated diagnostics, projected to grow from USD 0.76 billion in 2023 to USD 1.55 billion by 2033, representing an 8.7% market share. Semi-automated diagnostics also see growth, valuing USD 2.46 billion in 2023 and expected to reach USD 5.02 billion by 2033.
Autoimmune Disease Diagnostics Market Analysis By End Users
Hospitals remain the leading end-user segment for Autoimmune Disease Diagnostics with a market valuation of USD 4.51 billion in 2023, expected to grow to USD 9.22 billion by 2033, capturing 51.82% of the market share. Clinical laboratories and research institutions also form significant portions of the market, reflecting ongoing diagnostic innovation and testing needs.
Autoimmune Disease Diagnostics Market Analysis By Technology
In terms of technology, traditional diagnostic techniques comprising manual diagnostics account for USD 5.49 billion in 2023, projected to remain stable at a 63.07% market share. Advanced diagnostic techniques are expected to gain traction, increasing from USD 2.46 billion in 2023 to USD 5.02 billion by 2033.
Autoimmune Disease Diagnostics Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Autoimmune Disease Diagnostics Industry
Abbott Laboratories:
Abbott is a global healthcare company focusing on diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. They are at the forefront of innovation in autoimmune diagnostics.Thermo Fisher Scientific:
Thermo Fisher Scientific provides analytical instruments, reagents, and consumables for diagnostics and research. They actively develop solutions for autoimmune disease testing.Siemens Healthineers:
Siemens Healthineers specializes in imaging and diagnostic devices and solutions that significantly improve the efficiency of autoimmune disease diagnostics.Roche Diagnostics:
Roche is a leading player in the healthcare sector, focusing on innovative diagnostics solutions and tests that address various autoimmune diseases.Becton, Dickinson and Company (BD):
BD is known for its contributions to medical devices and diagnostics, focusing on enhancing the accuracy and speed of autoimmune disease diagnostics.We're grateful to work with incredible clients.
FAQs
What is the market size of the Autoimmune Disease Diagnostics Market Report in 2023?
The market size was $8.70 Billion in 2023. The report covers a forecast period of 2023 to 2033 with a projected compound annual growth rate of 7.2%.
What is CAGR for the forecast period 2023 to 2033?
The CAGR for the forecast period 2023 to 2033 is 7.2%, reflecting steady expansion driven by diagnostic technology improvements and broader testing adoption across care settings.
How big will the market be in 2033?
By 2033 the market is projected to reach $17.78 Billion, up from $8.70 Billion in 2023, reflecting a 7.2% CAGR across the 2023 to 2033 forecast interval.
Why is North America leading the market?
North America is the largest and fastest-growing region, rising from $3.38 Billion in 2023 to $6.91 Billion in 2033, supported by advanced labs, higher healthcare spending and established vendors.
Which companies are leading the Autoimmune Disease Diagnostics market?
Leading companies named in the report include Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, and Becton, Dickinson and Company (BD). These firms drive innovation and distribution.
Who are the primary end users in this market?
Primary end users include Hospitals, Clinical Laboratories, Home Care Settings, and Research Institutions, reflecting service delivery across acute care, laboratory testing, decentralized care, and scientific research environments.
What are the major test types covered in the market?
The market encompasses Laboratory Tests, Molecular Diagnostics, and Imaging Techniques, supporting detection and monitoring of autoimmune conditions across conventional serology, nucleic-acid assays, and imaging-based diagnostic approaches.
What is the forecast period covered by the report?
The report's forecast period spans 2023 to 2033, during which the market is expected to grow from $8.70 Billion to $17.78 Billion, guided by a 7.2% CAGR.
How is the market segmented by technology?
By technology, the market includes Traditional Diagnostic Techniques, Advanced Diagnostic Techniques, and Point of Care Testing, reflecting a mix of established laboratory methods, innovative platforms, and decentralized diagnostic solutions.
Why are point Of Care tests gaining traction?
Point-of-care tests are gaining traction because they deliver faster results, ease pressure on centralized laboratories, and support decentralized care pathways, aligning with increased demand for timely autoimmune disorder diagnostics.